{
    "abstract": "Background: RV144 is to date the only HIV vaccine trial to demonstrate efficacy, albeit rapidly waning over time. The HVTN 702 trial is currently evaluating in South Africa a similar vaccine formulation to that of RV144 for subtype C HIV with additional boosters (pox-protein regimen). Using a detailed stochastic individual-based network model of disease transmission calibrated to the HIV epidemic, we investigate population-level impact and maximum cost of an HIV vaccine to remain cost-effective. Methods: Consistent with the original pox-protein regimen, we model a primary series of five vaccinations meeting the goal of 50% cumulative efficacy 24 months after the first dose and include two-yearly boosters that maintain durable efficacy over 10 years. We simulate vaccination programs in South Africa starting in 2027 under various vaccine targeting and HIV treatment and prevention assumptions. Results: Our analysis shows that this partially effective vaccine could prevent, at catch-up vaccination with 60% coverage, up to 941,000 (15.6%) new infections between 2027 and 2047 assuming current trends of antiretroviral treatment. An impact of up to 697,000 (11.5%) infections prevented could be achieved by targeting age cohorts of highest incidence. Economic evaluation indicates that, if treatment scale-up was achieved, vaccination could be cost-effective at a total cost of less than $385 and $62 per 10-year series (cost-effectiveness thresholds of $5,691 and $750). Conclusions: While a partially effective, rapidly waning vaccine could help to prevent HIV infections, it will not eliminate HIV as a public health priority in sub-Saharan Africa. Vaccination is expected to be most effective under targeted delivery to age groups of highest HIV incidence. Awaiting results of trial, the introduction of vaccination should go in parallel with continued innovation in HIV prevention, including studies to determine the costs of delivery and feasibility and further research into products with greater efficacy and durability.",
    "bib_entries": {
        "b0005": null,
        "b0010": null,
        "b0015": {
            "authors": [
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Medlock"
                },
                {
                    "first": "Abhishek",
                    "initial": "A.",
                    "last": "Pandey"
                },
                {
                    "first": "Alyssa S.",
                    "initial": "A.S.",
                    "last": "Parpia"
                },
                {
                    "first": "Amber",
                    "initial": "A.",
                    "last": "Tang"
                },
                {
                    "first": "Laura A.",
                    "initial": "L.A.",
                    "last": "Skrip"
                },
                {
                    "first": "Alison P.",
                    "initial": "A.P.",
                    "last": "Galvani"
                }
            ],
            "doi": "10.1073/pnas.1620788114",
            "firstpage": "4017",
            "issn": "00278424",
            "lastpage": "4022",
            "pmid": "28320938",
            "pub_year": 2017,
            "title": "Effectiveness of UNAIDS targets and HIV vaccination across 127 countries",
            "volume": "114"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Lawrence",
                    "initial": "L.",
                    "last": "Corey"
                },
                {
                    "first": "Glenda E.",
                    "initial": "G.E.",
                    "last": "Gray"
                }
            ],
            "doi": "10.1073/pnas.1703236114",
            "firstpage": "3798",
            "issn": "00278424",
            "lastpage": "3800",
            "pmid": "28360202",
            "pub_year": 2017,
            "title": "Preventing acquisition of HIV is the only path to an AIDS-free generation",
            "volume": "114"
        },
        "b0025": null,
        "b0030": {
            "authors": [
                {
                    "first": "Nina D.",
                    "initial": "N.D.",
                    "last": "Russell"
                },
                {
                    "first": "Mary A.",
                    "initial": "M.A.",
                    "last": "Marovich"
                }
            ],
            "doi": "10.1097/COH.0000000000000322",
            "firstpage": "614",
            "issn": "1746630X",
            "lastpage": "619",
            "pmid": "27636503",
            "pub_year": 2016,
            "title": "Pox-Protein Public Private Partnership program and upcoming HIV vaccine efficacy trials",
            "volume": "11"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Supachai",
                    "initial": "S.",
                    "last": "Rerks-Ngarm"
                },
                {
                    "first": "Punnee",
                    "initial": "P.",
                    "last": "Pitisuttithum"
                },
                {
                    "first": "Sorachai",
                    "initial": "S.",
                    "last": "Nitayaphan"
                },
                {
                    "first": "Jaranit",
                    "initial": "J.",
                    "last": "Kaewkungwal"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Chiu"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Paris"
                },
                {
                    "first": "Nakorn",
                    "initial": "N.",
                    "last": "Premsri"
                },
                {
                    "first": "Chawetsan",
                    "initial": "C.",
                    "last": "Namwat"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "De Souza"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Adams"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Benenson"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Gurunathan"
                },
                {
                    "first": "Jim",
                    "initial": "J.",
                    "last": "Tartaglia"
                },
                {
                    "first": "John G.",
                    "initial": "J.G.",
                    "last": "McNeil"
                },
                {
                    "first": "Donald P.",
                    "initial": "D.P.",
                    "last": "Francis"
                },
                {
                    "first": "Donald",
                    "initial": "D.",
                    "last": "Stablein"
                },
                {
                    "first": "Deborah L.",
                    "initial": "D.L.",
                    "last": "Birx"
                },
                {
                    "first": "Supamit",
                    "initial": "S.",
                    "last": "Chunsuttiwat"
                },
                {
                    "first": "Chirasak",
                    "initial": "C.",
                    "last": "Khamboonruang"
                },
                {
                    "first": "Prasert",
                    "initial": "P.",
                    "last": "Thongcharoen"
                },
                {
                    "first": "Merlin L.",
                    "initial": "M.L.",
                    "last": "Robb"
                },
                {
                    "first": "Nelson L.",
                    "initial": "N.L.",
                    "last": "Michael"
                },
                {
                    "first": "Prayura",
                    "initial": "P.",
                    "last": "Kunasol"
                },
                {
                    "first": "Jerome H.",
                    "initial": "J.H.",
                    "last": "Kim"
                }
            ],
            "doi": "10.1056/NEJMoa0908492",
            "firstpage": "2209",
            "issn": "00284793",
            "lastpage": "2220",
            "pmid": "19843557",
            "pub_year": 2009,
            "title": "Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand",
            "volume": "361"
        },
        "b0040": null,
        "b0045": {
            "authors": [
                {
                    "first": "Supachai",
                    "initial": "S.",
                    "last": "Rerks-Ngarm"
                },
                {
                    "first": "Punnee",
                    "initial": "P.",
                    "last": "Pitisuttithum"
                },
                {
                    "first": "Jean Louis",
                    "initial": "J.L.",
                    "last": "Excler"
                },
                {
                    "first": "Sorachai",
                    "initial": "S.",
                    "last": "Nitayaphan"
                },
                {
                    "first": "Jaranit",
                    "initial": "J.",
                    "last": "Kaewkungwal"
                },
                {
                    "first": "Nakorn",
                    "initial": "N.",
                    "last": "Premsri"
                },
                {
                    "first": "Prayura",
                    "initial": "P.",
                    "last": "Kunasol"
                },
                {
                    "first": "Nicos",
                    "initial": "N.",
                    "last": "Karasavvas"
                },
                {
                    "first": "Alexandra",
                    "initial": "A.",
                    "last": "Schuetz"
                },
                {
                    "first": "Viseth",
                    "initial": "V.",
                    "last": "Ngauy"
                },
                {
                    "first": "Faruk",
                    "initial": "F.",
                    "last": "Sinangil"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Dawson"
                },
                {
                    "first": "Allan C.",
                    "initial": "A.C.",
                    "last": "DeCamp"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Phogat"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Garunathan"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Tartaglia"
                },
                {
                    "first": "Carlos",
                    "initial": "C.",
                    "last": "Diazgranados"
                },
                {
                    "first": "Silvia",
                    "initial": "S.",
                    "last": "Ratto-Kim"
                },
                {
                    "first": "Poonam",
                    "initial": "P.",
                    "last": "Pegu"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Eller"
                },
                {
                    "first": "Chitraporn",
                    "initial": "C.",
                    "last": "Karnasuta"
                },
                {
                    "first": "David C.",
                    "initial": "D.C.",
                    "last": "Montefiori"
                },
                {
                    "first": "Sheetal",
                    "initial": "S.",
                    "last": "Sawant"
                },
                {
                    "first": "Nathan",
                    "initial": "N.",
                    "last": "Vandergrift"
                },
                {
                    "first": "Saintedym",
                    "initial": "S.",
                    "last": "Wills"
                },
                {
                    "first": "Georgia D.",
                    "initial": "G.D.",
                    "last": "Tomaras"
                },
                {
                    "first": "Merlin L.",
                    "initial": "M.L.",
                    "last": "Robb"
                },
                {
                    "first": "Nelson L.",
                    "initial": "N.L.",
                    "last": "Michael"
                },
                {
                    "first": "Jerome H.",
                    "initial": "J.H.",
                    "last": "Kim"
                },
                {
                    "first": "Sandhya",
                    "initial": "S.",
                    "last": "Vasan"
                },
                {
                    "first": "Robert J.",
                    "initial": "R.J.",
                    "last": "O\u2019Connell"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1093/infdis/jix099",
            "firstpage": "1255",
            "issn": "00221899",
            "lastpage": "1263",
            "pmid": "28329190",
            "pub_year": 2017,
            "title": "Randomized, double-blind evaluation of late boost strategies for HIV-uninfected vaccine recipients in the RV144 HIV vaccine efficacy trial",
            "volume": "215"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Kristin N.",
                    "initial": "K.N.",
                    "last": "Harper"
                }
            ],
            "doi": "10.1097/QAD.0000000000001296",
            "issn": "02699370",
            "lastpage": "N2",
            "pmid": "27755102",
            "pub_year": 2017,
            "title": "Notes and quotes",
            "volume": "31"
        },
        "b0055": null,
        "b0060": {
            "authors": [
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Rehle"
                },
                {
                    "first": "Leigh",
                    "initial": "L.",
                    "last": "Johnson"
                },
                {
                    "first": "Timothy",
                    "initial": "T.",
                    "last": "Hallett"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Mahy"
                },
                {
                    "first": "Andrea",
                    "initial": "A.",
                    "last": "Kim"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Odido"
                },
                {
                    "first": "Dorina",
                    "initial": "D.",
                    "last": "Onoya"
                },
                {
                    "first": "Sean",
                    "initial": "S.",
                    "last": "Jooste"
                },
                {
                    "first": "Olive",
                    "initial": "O.",
                    "last": "Shisana"
                },
                {
                    "first": "Adrian",
                    "initial": "A.",
                    "last": "Puren"
                },
                {
                    "first": "Bharat",
                    "initial": "B.",
                    "last": "Parekh"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Stover"
                }
            ],
            "doi": "10.1371/journal.pone.0133255",
            "issn": "19326203",
            "pmid": "26230949",
            "pub_year": 2015,
            "title": "A comparison of South African national HIV incidence estimates: A critical appraisal of different methods",
            "volume": "10"
        },
        "b0065": null,
        "b0070": {
            "authors": [
                {
                    "first": "Tulio",
                    "initial": "T.",
                    "last": "de Oliveira"
                },
                {
                    "first": "Ayesha B.M.",
                    "initial": "A.B.M.",
                    "last": "Kharsany"
                },
                {
                    "first": "Tiago",
                    "initial": "T.",
                    "last": "Gr\u00e4f"
                },
                {
                    "first": "Cherie",
                    "initial": "C.",
                    "last": "Cawood"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Khanyile"
                },
                {
                    "first": "Anneke",
                    "initial": "A.",
                    "last": "Grobler"
                },
                {
                    "first": "Adrian",
                    "initial": "A.",
                    "last": "Puren"
                },
                {
                    "first": "Savathree",
                    "initial": "S.",
                    "last": "Madurai"
                },
                {
                    "first": "Cheryl",
                    "initial": "C.",
                    "last": "Baxter"
                },
                {
                    "first": "Quarraisha Abdool",
                    "initial": "Q.A.",
                    "last": "Karim"
                },
                {
                    "first": "Salim S.Abdool",
                    "initial": "S.S.A.",
                    "last": "Karim"
                }
            ],
            "doi": "10.1016/S2352-3018(16)30186-2",
            "firstpage": "e41",
            "issn": "23523018",
            "lastpage": "e50",
            "pmid": "27914874",
            "pub_year": 2017,
            "title": "Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study",
            "volume": "4"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Jan A.C.",
                    "initial": "J.A.C.",
                    "last": "Hontelez"
                },
                {
                    "first": "Nico",
                    "initial": "N.",
                    "last": "Nagelkerke"
                },
                {
                    "first": "Till",
                    "initial": "T.",
                    "last": "B\u00e4rnighausen"
                },
                {
                    "first": "Roel",
                    "initial": "R.",
                    "last": "Bakker"
                },
                {
                    "first": "Frank",
                    "initial": "F.",
                    "last": "Tanser"
                },
                {
                    "first": "Marie Louise",
                    "initial": "M.L.",
                    "last": "Newell"
                },
                {
                    "first": "Mark N.",
                    "initial": "M.N.",
                    "last": "Lurie"
                },
                {
                    "first": "Rob",
                    "initial": "R.",
                    "last": "Baltussen"
                },
                {
                    "first": "Sake J.",
                    "initial": "S.J.",
                    "last": "de Vlas"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.06.059",
            "firstpage": "6100",
            "issn": "0264410X",
            "lastpage": "6106",
            "pmid": "21703321",
            "pub_year": 2011,
            "title": "The potential impact of RV144-like vaccines in rural South Africa: A study using the STDSIM microsimulation model",
            "volume": "29"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Jennifer A.",
                    "initial": "J.A.",
                    "last": "Smith"
                },
                {
                    "first": "Sarah Jane",
                    "initial": "S.J.",
                    "last": "Anderson"
                },
                {
                    "first": "Kate L.",
                    "initial": "K.L.",
                    "last": "Harris"
                },
                {
                    "first": "Jessica B.",
                    "initial": "J.B.",
                    "last": "McGillen"
                },
                {
                    "first": "Edward",
                    "initial": "E.",
                    "last": "Lee"
                },
                {
                    "first": "Geoff P.",
                    "initial": "G.P.",
                    "last": "Garnett"
                },
                {
                    "first": "Timothy B.",
                    "initial": "T.B.",
                    "last": "Hallett"
                }
            ],
            "doi": "10.1016/S2352-3018(16)30036-4",
            "firstpage": "e289",
            "issn": "23523018",
            "lastpage": "e296",
            "pmid": "27365203",
            "pub_year": 2016,
            "title": "Maximising HIV prevention by balancing the opportunities of today with the promises of tomorrow: a modelling study",
            "volume": "3"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Kyeen M.",
                    "initial": "K.M.",
                    "last": "Andersson"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Stover"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.06.060",
            "firstpage": "6092",
            "issn": "0264410X",
            "lastpage": "6099",
            "pmid": "21703322",
            "pub_year": 2011,
            "title": "The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand",
            "volume": "29"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Thomas M.",
                    "initial": "T.M.",
                    "last": "Harmon"
                },
                {
                    "first": "Kevin A.",
                    "initial": "K.A.",
                    "last": "Fisher"
                },
                {
                    "first": "Margaret G.",
                    "initial": "M.G.",
                    "last": "McGlynn"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Stover"
                },
                {
                    "first": "Mitchell J.",
                    "initial": "M.J.",
                    "last": "Warren"
                },
                {
                    "first": "Yu",
                    "initial": "Y.",
                    "last": "Teng"
                },
                {
                    "first": "Arne",
                    "initial": "A.",
                    "last": "N\u00e4veke"
                }
            ],
            "doi": "10.1371/journal.pone.0146387",
            "issn": "19326203",
            "pmid": "26731116",
            "pub_year": 2016,
            "title": "Exploring the potential health impact and cost-effectiveness of AIDS vaccine within a comprehensive HIV/AIDS response in lowand middle-income countries",
            "volume": "11"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Nishila",
                    "initial": "N.",
                    "last": "Moodley"
                },
                {
                    "first": "Glenda",
                    "initial": "G.",
                    "last": "Gray"
                },
                {
                    "first": "Melanie",
                    "initial": "M.",
                    "last": "Bertram"
                }
            ],
            "doi": "10.1097/MD.0000000000002528",
            "issn": "00257974",
            "pmid": "26825890",
            "pub_year": 2016,
            "title": "The case for adolescent hiv vaccination in South Africa: A cost-effectiveness analysis",
            "volume": "95"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Nishila",
                    "initial": "N.",
                    "last": "Moodley"
                },
                {
                    "first": "Glenda",
                    "initial": "G.",
                    "last": "Gray"
                },
                {
                    "first": "Melanie",
                    "initial": "M.",
                    "last": "Bertram"
                }
            ],
            "doi": "10.1186/s12889-016-2959-3",
            "issn": "14712458",
            "pmid": "27079900",
            "pub_year": 2016,
            "title": "Projected economic evaluation of the national implementation of a hypothetical HIV vaccination program among adolescents in South Africa, 2012",
            "volume": "16"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Catherine A.",
                    "initial": "C.A.",
                    "last": "Hankins"
                },
                {
                    "first": "John W.",
                    "initial": "J.W.",
                    "last": "Glasser"
                },
                {
                    "first": "Robert T.",
                    "initial": "R.T.",
                    "last": "Chen"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.07.001",
            "firstpage": "6069",
            "issn": "0264410X",
            "lastpage": "6071",
            "pmid": "21762753",
            "pub_year": 2011,
            "title": "Modeling the impact of RV144-like vaccines on HIV transmission",
            "volume": "29"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Andrew N.",
                    "initial": "A.N.",
                    "last": "Phillips"
                },
                {
                    "first": "Valentina",
                    "initial": "V.",
                    "last": "Cambiano"
                },
                {
                    "first": "Fumiyo",
                    "initial": "F.",
                    "last": "Nakagawa"
                },
                {
                    "first": "Deborah",
                    "initial": "D.",
                    "last": "Ford"
                },
                {
                    "first": "Jens D.",
                    "initial": "J.D.",
                    "last": "Lundgren"
                },
                {
                    "first": "Edith",
                    "initial": "E.",
                    "last": "Roset-Bahmanyar"
                },
                {
                    "first": "Fran\u00e7ois",
                    "initial": "F.",
                    "last": "Roman"
                },
                {
                    "first": "Thierry",
                    "initial": "T.",
                    "last": "Van Effelterre"
                }
            ],
            "doi": "10.1371/journal.pone.0107214",
            "issn": "19326203",
            "pmid": "25207973",
            "pub_year": 2014,
            "title": "Potential future impact of a partially effective HIV vaccine in a southern African setting",
            "volume": "9"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Blythe",
                    "initial": "B.",
                    "last": "Adamson"
                },
                {
                    "first": "Dobromir",
                    "initial": "D.",
                    "last": "Dimitrov"
                },
                {
                    "first": "Beth",
                    "initial": "B.",
                    "last": "Devine"
                },
                {
                    "first": "Ruanne",
                    "initial": "R.",
                    "last": "Barnabas"
                }
            ],
            "doi": "10.1007/s41669-016-0009-9",
            "issn": "25094262",
            "pub_year": 2017,
            "title": "The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review",
            "volume": "1"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "De Montigny"
                },
                {
                    "first": "Blythe J.S.",
                    "initial": "B.J.S.",
                    "last": "Adamson"
                },
                {
                    "first": "Beno\u00eet R.",
                    "initial": "B.R.",
                    "last": "M\u00e2sse"
                },
                {
                    "first": "Louis P.",
                    "initial": "L.P.",
                    "last": "Garrison"
                },
                {
                    "first": "James G.",
                    "initial": "J.G.",
                    "last": "Kublin"
                },
                {
                    "first": "Peter B.",
                    "initial": "P.B.",
                    "last": "Gilbert"
                },
                {
                    "first": "Dobromir T.",
                    "initial": "D.T.",
                    "last": "Dimitrov"
                }
            ],
            "doi": "10.1038/s41598-018-24268-4",
            "issn": "20452322",
            "pmid": "29666455",
            "pub_year": 2018,
            "title": "Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study",
            "volume": "8"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Bershteyn"
                },
                {
                    "first": "Daniel J.",
                    "initial": "D.J.",
                    "last": "Klein"
                },
                {
                    "first": "Philip A.",
                    "initial": "P.A.",
                    "last": "Eckhoff"
                }
            ],
            "doi": "10.1098/rsif.2013.0613",
            "issn": "17425689",
            "pmid": "23985734",
            "pub_year": 2013,
            "title": "Age-dependent partnering and the HIV transmission chain: A microsimulation analysis",
            "volume": "10"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Daniel J.",
                    "initial": "D.J.",
                    "last": "Klein"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Bershteyn"
                },
                {
                    "first": "Philip A.",
                    "initial": "P.A.",
                    "last": "Eckhoff"
                }
            ],
            "doi": "10.1097/QAD.0000000000000081",
            "firstpage": "S47",
            "issn": "02699370",
            "lastpage": "S59",
            "pmid": "24468946",
            "pub_year": 2014,
            "title": "Dropout and re-enrollment: Implications for epidemiological projections of treatment programs",
            "volume": "28"
        },
        "b0135": null,
        "b0140": {
            "authors": [
                {
                    "first": "Merlin L.",
                    "initial": "M.L.",
                    "last": "Robb"
                },
                {
                    "first": "Supachai",
                    "initial": "S.",
                    "last": "Rerks-Ngarm"
                },
                {
                    "first": "Sorachai",
                    "initial": "S.",
                    "last": "Nitayaphan"
                },
                {
                    "first": "Punnee",
                    "initial": "P.",
                    "last": "Pitisuttithum"
                },
                {
                    "first": "Jaranit",
                    "initial": "J.",
                    "last": "Kaewkungwal"
                },
                {
                    "first": "Prayura",
                    "initial": "P.",
                    "last": "Kunasol"
                },
                {
                    "first": "Chirasak",
                    "initial": "C.",
                    "last": "Khamboonruang"
                },
                {
                    "first": "Prasert",
                    "initial": "P.",
                    "last": "Thongcharoen"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Morgan"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Benenson"
                },
                {
                    "first": "Robert M.",
                    "initial": "R.M.",
                    "last": "Paris"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Chiu"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Adams"
                },
                {
                    "first": "Donald",
                    "initial": "D.",
                    "last": "Francis"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Gurunathan"
                },
                {
                    "first": "Jim",
                    "initial": "J.",
                    "last": "Tartaglia"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Gilbert"
                },
                {
                    "first": "Don",
                    "initial": "D.",
                    "last": "Stablein"
                },
                {
                    "first": "Nelson L.",
                    "initial": "N.L.",
                    "last": "Michael"
                },
                {
                    "first": "Jerome H.",
                    "initial": "J.H.",
                    "last": "Kim"
                }
            ],
            "doi": "10.1016/S1473-3099(12)70088-9",
            "firstpage": "531",
            "issn": "14733099",
            "lastpage": "537",
            "pmid": "22652344",
            "pub_year": 2012,
            "title": "Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A post-hoc analysis of the Thai phase 3 efficacy trial RV 144",
            "volume": "12"
        },
        "b0145": null,
        "b0150": {
            "authors": [
                {
                    "first": "M\u00e9lanie",
                    "initial": "M.",
                    "last": "Plazy"
                },
                {
                    "first": "Kamal El",
                    "initial": "K.E.",
                    "last": "Farouki"
                },
                {
                    "first": "Collins",
                    "initial": "C.",
                    "last": "Iwuji"
                },
                {
                    "first": "Nonhlanhla",
                    "initial": "N.",
                    "last": "Okesola"
                },
                {
                    "first": "Joanna",
                    "initial": "J.",
                    "last": "Orne-Gliemann"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Larmarange"
                },
                {
                    "first": "France",
                    "initial": "F.",
                    "last": "Lert"
                },
                {
                    "first": "Marie Louise",
                    "initial": "M.L.",
                    "last": "Newell"
                },
                {
                    "first": "Fran\u00e7ois",
                    "initial": "F.",
                    "last": "Dabis"
                },
                {
                    "first": "Rosemary",
                    "initial": "R.",
                    "last": "Dray-Spira"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.7448/IAS.19.1.20913",
            "issn": "17582652",
            "pmid": "27258430",
            "pub_year": 2016,
            "title": "Access to HIV care in the context of universal test and treat: Challenges within the ANRS 12249 TasP cluster-randomized trial in rural South Africa",
            "volume": "19"
        },
        "b0155": null,
        "b0160": null,
        "b0165": {
            "authors": [
                {
                    "first": "Bruce A.",
                    "initial": "B.A.",
                    "last": "Larson"
                }
            ],
            "doi": "10.1186/1478-7547-11-18",
            "firstpage": "1",
            "issn": "14787547",
            "lastpage": "6",
            "pub_year": 2013,
            "title": "Calculating disability-adjusted-life-years lost (DALYs) in discrete-time",
            "volume": "11"
        },
        "b0190": {
            "authors": [
                {
                    "first": "Peter J.",
                    "initial": "P.J.",
                    "last": "Neumann"
                },
                {
                    "first": "Joshua T.",
                    "initial": "J.T.",
                    "last": "Cohen"
                }
            ],
            "doi": "10.1056/NEJMp1512009",
            "firstpage": "2595",
            "issn": "00284793",
            "lastpage": "2597",
            "pmid": "26580666",
            "pub_year": 2015,
            "title": "Measuring the value of prescription drugs",
            "volume": "373"
        },
        "b0195": null,
        "b0200": {
            "authors": [
                {
                    "first": "Nigel",
                    "initial": "N.",
                    "last": "Gregson"
                },
                {
                    "first": "Keiron",
                    "initial": "K.",
                    "last": "Sparrowhawk"
                },
                {
                    "first": "Josephine",
                    "initial": "J.",
                    "last": "Mauskopf"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Paul"
                }
            ],
            "doi": "10.1038/nrd1633",
            "firstpage": "121",
            "issn": "14741776",
            "lastpage": "130",
            "pmid": "15688076",
            "pub_year": 2005,
            "title": "Pricing medicines: Theory and practice, challenges and opportunities",
            "volume": "4"
        },
        "b0205": {
            "authors": [
                {
                    "first": "Beth",
                    "initial": "B.",
                    "last": "Woods"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Revill"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Sculpher"
                },
                {
                    "first": "Karl",
                    "initial": "K.",
                    "last": "Claxton"
                }
            ],
            "doi": "10.1016/j.jval.2016.02.017",
            "firstpage": "929",
            "issn": "10983015",
            "lastpage": "935",
            "pmid": "27987642",
            "pub_year": 2016,
            "title": "Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research",
            "volume": "19"
        },
        "b0210": null,
        "b0215": {
            "authors": [
                {
                    "first": "Peter B.",
                    "initial": "P.B.",
                    "last": "Gilbert"
                },
                {
                    "first": "Ying",
                    "initial": "Y.",
                    "last": "Huang"
                }
            ],
            "doi": "10.1515/em-2015-0007",
            "firstpage": "93",
            "issn": "21949263",
            "lastpage": "112",
            "pub_year": 2016,
            "title": "Predicting Overall Vaccine Efficacy in a New Setting by Re-calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy",
            "volume": "5"
        },
        "b0220": {
            "authors": [
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Jit"
                },
                {
                    "first": "Walter",
                    "initial": "W.",
                    "last": "Mibei"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.06.084",
            "firstpage": "3788",
            "issn": "0264410X",
            "lastpage": "3794",
            "pmid": "26144897",
            "pub_year": 2015,
            "title": "Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review",
            "volume": "33"
        },
        "b0225": {
            "authors": [
                {
                    "first": "Indres",
                    "initial": "I.",
                    "last": "Moodley"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Tathiah"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Mubaiwa"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Denny"
                }
            ],
            "doi": "10.7196/SAMJ.6414",
            "firstpage": "318",
            "issn": "02569574",
            "lastpage": "321",
            "pmid": "23971122",
            "pub_year": 2013,
            "title": "High uptake of Gardasil vaccine among 9 - 12-yearold schoolgirls participating in an HPV vaccination demonstration project in Kwazulu-Natal, South Africa",
            "volume": "103"
        },
        "b0230": {
            "authors": [
                {
                    "first": "Khangelani",
                    "initial": "K.",
                    "last": "Zuma"
                },
                {
                    "first": "Thembile",
                    "initial": "T.",
                    "last": "Mzolo"
                },
                {
                    "first": "Elias",
                    "initial": "E.",
                    "last": "Makonko"
                }
            ],
            "doi": "10.2989/16085906.2011.626283",
            "firstpage": "189",
            "issn": "16085906",
            "lastpage": "194",
            "pub_year": 2011,
            "title": "Determinants of age at sexual debut and associated risks among South African youths",
            "volume": "10"
        },
        "b0235": null,
        "b0240": null,
        "b0245": null,
        "b0250": {
            "authors": [
                {
                    "first": "Beth",
                    "initial": "B.",
                    "last": "Woods"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Revill"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Sculpher"
                },
                {
                    "first": "Karl",
                    "initial": "K.",
                    "last": "Claxton"
                }
            ],
            "doi": "10.1016/j.jval.2016.02.017",
            "firstpage": "929",
            "issn": "10983015",
            "lastpage": "935",
            "pmid": "27987642",
            "pub_year": 2016,
            "title": "Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research",
            "volume": "19"
        },
        "b0255": null,
        "b0260": {
            "authors": [
                {
                    "first": "Cristine J.",
                    "initial": "C.J.",
                    "last": "Cooper"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Metch"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Dragavon"
                },
                {
                    "first": "Robert W.",
                    "initial": "R.W.",
                    "last": "Coombs"
                },
                {
                    "first": "Lindsey R.",
                    "initial": "L.R.",
                    "last": "Baden"
                }
            ],
            "doi": "10.1001/jama.2010.926",
            "firstpage": "275",
            "issn": "00987484",
            "lastpage": "283",
            "pmid": "20639561",
            "pub_year": 2010,
            "title": "Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients",
            "volume": "304"
        },
        "b0265": {
            "authors": [
                {
                    "first": "Yegor",
                    "initial": "Y.",
                    "last": "Voronin"
                },
                {
                    "first": "Helene",
                    "initial": "H.",
                    "last": "Zinszner"
                },
                {
                    "first": "Carissa",
                    "initial": "C.",
                    "last": "Karg"
                },
                {
                    "first": "Katie",
                    "initial": "K.",
                    "last": "Brooks"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Coombs"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Hural"
                },
                {
                    "first": "Renee",
                    "initial": "R.",
                    "last": "Holt"
                },
                {
                    "first": "Pat",
                    "initial": "P.",
                    "last": "Fast"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Allen"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Busch"
                },
                {
                    "first": "Ulrich",
                    "initial": "U.",
                    "last": "Fruth"
                },
                {
                    "first": "Hana",
                    "initial": "H.",
                    "last": "Golding"
                },
                {
                    "first": "Surender",
                    "initial": "S.",
                    "last": "Khurana"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Mulenga"
                },
                {
                    "first": "Sheila",
                    "initial": "S.",
                    "last": "Peel"
                },
                {
                    "first": "Marco",
                    "initial": "M.",
                    "last": "Schito"
                },
                {
                    "first": "Nomampondo",
                    "initial": "N.",
                    "last": "Barnabas"
                },
                {
                    "first": "Christopher",
                    "initial": "C.",
                    "last": "Bentsen"
                },
                {
                    "first": "Barney",
                    "initial": "B.",
                    "last": "Graham"
                },
                {
                    "first": "Glenda",
                    "initial": "G.",
                    "last": "Gray"
                },
                {
                    "first": "Andrew",
                    "initial": "A.",
                    "last": "Levin"
                },
                {
                    "first": "Margaret",
                    "initial": "M.",
                    "last": "McCluskey"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "O'Connell"
                },
                {
                    "first": "Bill",
                    "initial": "B.",
                    "last": "Snow"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Ware"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.10.040",
            "firstpage": "1243",
            "issn": "0264410X",
            "lastpage": "1249",
            "pmid": "25649349",
            "pub_year": 2015,
            "title": "HIV vaccine-induced sero-reactivity: A challenge for trial participants, researchers, and physicians",
            "volume": "33"
        }
    },
    "body_text": [
        {
            "endOffset": 40025,
            "parents": [],
            "secId": "s0010",
            "sentence": "Strategies included a wide range of age- and gender-specific targeting scenarios at low (30%), medium (50%) and high (80%) coverage using two distinct roll-out approaches starting in 2027, the earliest realistic date of introduction: Cohort vaccination, aiming for immunization and follow-up boosting of a pre-specified proportion (coverage) of individuals at a particular target age every year over the period between 2027 and 2047 (Table S1), and catch-up vaccination scenarios (Table S2) were implemented for individuals within a pre-specified age range starting in 2027 with a linearly increasing coverage to reach the ramp-up coverage in 2032, followed by cohort-like vaccination from 2032 onwards for individuals aging into the target range at a maintenance coverage which was 20% higher than the ramp-up coverage.",
            "startOffset": 39205,
            "title": "Methods"
        },
        {
            "endOffset": 47831,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Results"
                }
            ],
            "secId": "s0025",
            "sentence": "This indicates that introduction of oral PrEP for high-risk groups starting in 2016 will have a smaller impact on overall HIV incidence as compared to ART scale-up.",
            "startOffset": 47667,
            "title": "Incidence given no HIV vaccine"
        },
        {
            "endOffset": 27870,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 27869,
                    "startOffset": 27866
                }
            },
            "secId": "s0005",
            "sentence": "This, and the difficulty in rolling out existing methods of HIV prevention (such as medical male circumcision, and oral pre-exposure prophylaxis) to key populations, highlight the need for a preventative vaccine [4].",
            "startOffset": 27654,
            "title": "Introduction"
        },
        {
            "endOffset": 28881,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 28625,
                    "startOffset": 28620
                },
                "b0045": {
                    "endOffset": 28625,
                    "startOffset": 28620
                }
            },
            "secId": "s0005",
            "sentence": "Though the efficacy of the vaccine appeared to be greatest shortly after the last dose and then waned rapidly, a recent follow-up study [8,9] in which a subset of RV144 participants was re-vaccinated up to six years after enrollment reported immune memory responses two weeks after re-vaccination, offering hope that an extended immunization schedule could potentially increase vaccine durability.",
            "startOffset": 28484,
            "title": "Introduction"
        },
        {
            "endOffset": 33030,
            "parents": [],
            "secId": "s0005",
            "sentence": "Here, we estimate the impact of a 10-year vaccine regimen (primary series and boosters) within a 20-year vaccination program on the HIV epidemic in South Africa using an individual-based network model of HIV transmission structured by age, sex and risk.",
            "startOffset": 32777,
            "title": "Introduction"
        },
        {
            "endOffset": 40627,
            "parents": [],
            "secId": "s0010",
            "sentence": "In the most pessimistic scenario (Status Quo without PrEP), we stipulated that guideline changes have no impact on ART initiation.",
            "startOffset": 40497,
            "title": "Methods"
        },
        {
            "endOffset": 48258,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0140": {
                    "endOffset": 47983,
                    "startOffset": 47979
                }
            },
            "secId": "s0030",
            "sentence": "Fitting the impulse and exponential decay model to known time-dependent vaccine efficacy estimates [28] for the first six months of the RV144 regimen, and adjusting the model parameters such that the goal of 50% efficacy at the month 24 endpoint is met, results in a time-dependent efficacy curve (Fig. 2, red curve) peaking at 80% shortly after the additional month 12 booster.",
            "startOffset": 47880,
            "title": "Time-dependent and cumulative vaccine efficacy"
        },
        {
            "endOffset": 61543,
            "parents": [],
            "secId": "s0045",
            "sentence": "DALY calculations were truncated at the vaccination endpoint in 2047, i.e. vaccination could add at most 20 additional years of life from the start of vaccination to the endpoint.",
            "startOffset": 61364,
            "title": "Discussion"
        },
        {
            "endOffset": 63691,
            "parents": [],
            "secId": "s0065",
            "sentence": "B., H.R., G.G. interpreted the data and contributed to writing the manuscript.",
            "startOffset": 63613,
            "title": "Author contributions"
        },
        {
            "endOffset": 41190,
            "parents": [],
            "secId": "s0010",
            "sentence": "A moderately optimistic scenario (\u2018Status Quo with PrEP\u2019) maintained ART linkage assumptions of \u2018Status Quo without PrEP\u2019, but assumed reaching oral PrEP coverage of 30% by 2027 and maintained this level for high risk men and women under 30 years of age.",
            "startOffset": 40936,
            "title": "Methods"
        },
        {
            "endOffset": 35841,
            "parents": [],
            "secId": "s0010",
            "sentence": "A detailed model description, user tutorials, model installer, and source code are available for download at http://idmod.org/software.",
            "startOffset": 35706,
            "title": "Methods"
        },
        {
            "endOffset": 47114,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Results"
                }
            ],
            "secId": "s0025",
            "sentence": "During the same time period, annual HIV incidence in men aged 15 to 49 is projected to decline from 0.9% to 0.7%, 0.68% and 0.41% respectively (Fig. 1).",
            "startOffset": 46962,
            "title": "Incidence given no HIV vaccine"
        },
        {
            "endOffset": 44308,
            "parents": [],
            "secId": "s0010",
            "sentence": "Based on strategy-dependent changes in total discounted healthcare costs and DALYs, as compared to the reference with no vaccine, we estimated the maximum vaccination cost level for a vaccination strategy to be cost-effective.",
            "startOffset": 44082,
            "title": "Methods"
        },
        {
            "endOffset": 31606,
            "parents": [],
            "secId": "s0005",
            "sentence": "First, an optimal vaccination schedule should account for any waning efficacy, recommendations for booster dose frequency, and rate of attrition from the recommended series of HIV vaccine doses.",
            "startOffset": 31412,
            "title": "Introduction"
        },
        {
            "endOffset": 56188,
            "parents": [],
            "refoffsets": {
                "b0225": {
                    "endOffset": 56017,
                    "startOffset": 56013
                },
                "b0230": {
                    "endOffset": 56187,
                    "startOffset": 56183
                }
            },
            "secId": "s0045",
            "sentence": "Although adolescent HIV vaccination has the potential of reaching high coverage in South Africa through school-based programs (such as Human Papilloma Virus routine vaccination [45]), our modeling results (see Table 2 and Table S3) do not make a strong case for vaccinating before the age of sexual debut, estimated at a median of 18 years of age [46].",
            "startOffset": 55836,
            "title": "Discussion"
        },
        {
            "endOffset": 56299,
            "parents": [],
            "secId": "s0045",
            "sentence": "The same conclusion applies to the potential impact on vertical transmission by vaccinating 15-year-old women.",
            "startOffset": 56189,
            "title": "Discussion"
        },
        {
            "endOffset": 46479,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Results"
                }
            ],
            "secId": "s0025",
            "sentence": "Varying assumptions about linkage to and drop-out from ART and uptake of oral PrEP between 2016 and the presumed start of vaccination in 2027 results in distinct future ART coverage and incidence estimates.",
            "startOffset": 46273,
            "title": "Incidence given no HIV vaccine"
        },
        {
            "endOffset": 35195,
            "parents": [],
            "secId": "s0010",
            "sentence": "To ensure that our analysis reflected the realities of the HIV epidemic and the health system in South Africa, we iteratively engaged South African government, academic and community stakeholders through one-on-one interviews, a vaccine access planning summit and a public health impact modelling workshop during which preliminary results of this work were presented and discussed.",
            "startOffset": 34814,
            "title": "Methods"
        },
        {
            "endOffset": 39204,
            "parents": [],
            "secId": "s0010",
            "sentence": "Based on consultations with the P5 GAC, we evaluated 30 implementation strategies for HIV vaccine targeting and implementation.",
            "startOffset": 39077,
            "title": "Methods"
        },
        {
            "endOffset": 43609,
            "parents": [],
            "secId": "s0010",
            "sentence": "We measured health outcomes in DALYs to capture changes in both the length and quality of life for individuals in the population.",
            "startOffset": 43480,
            "title": "Methods"
        },
        {
            "endOffset": 56542,
            "parents": [],
            "refoffsets": {
                "b0235": {
                    "endOffset": 56430,
                    "startOffset": 56426
                },
                "b0240": {
                    "endOffset": 56541,
                    "startOffset": 56537
                }
            },
            "secId": "s0045",
            "sentence": "Prevention of mother-to-child transmission is efficacious in South Africa (only 1.3% of live births in 2017 were HIV positive [47]) and only 12% of live births are given at age 19 or younger whereas 70% of births are given at ages 20\u201334 [48].",
            "startOffset": 56300,
            "title": "Discussion"
        },
        {
            "endOffset": 58742,
            "parents": [],
            "secId": "s0045",
            "sentence": "There are several major limitations to this analysis.",
            "startOffset": 58689,
            "title": "Discussion"
        },
        {
            "endOffset": 57408,
            "parents": [],
            "secId": "s0045",
            "sentence": "We derived estimates for the maximum vaccine cost (10-year regimen, including product and delivery costs) to remain cost-effective averagingfor two different treatment and prevention scale-up projections.",
            "startOffset": 57204,
            "title": "Discussion"
        },
        {
            "endOffset": 27456,
            "parents": [],
            "secId": "s0005",
            "sentence": "Reaching the ambitious goal of 90-90-90 by 2020 (90% of people infected with HIV should know their status, with 90% of people diagnosed with HIV infection to be receiving antiretroviral treatment and 90% of people receiving treatment to have viral suppression) would not only diminish a substantial treatment gap but also prevent new infections.",
            "startOffset": 27111,
            "title": "Introduction"
        },
        {
            "endOffset": 29073,
            "parents": [],
            "secId": "s0005",
            "sentence": "The ongoing HVTN 702 study is a multi-site, randomized, double-blinded, placebo-controlled clinical trial designed to test a regimen adapted to HIV Clade C exposed populations in South Africa.",
            "startOffset": 28881,
            "title": "Introduction"
        },
        {
            "endOffset": 42982,
            "parents": [],
            "secId": "s0010",
            "sentence": "The number of vaccine regimens distributed was defined as the number of primary series completed.",
            "startOffset": 42885,
            "title": "Methods"
        },
        {
            "endOffset": 41569,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 41568,
                    "startOffset": 41564
                }
            },
            "secId": "s0010",
            "sentence": "We did not incorporate behavior change into the \u2018Fast Track with PrEP\u2019 scenario, as detailed in the Fast Track UNAIDS goals [31].",
            "startOffset": 41440,
            "title": "Methods"
        },
        {
            "endOffset": 59790,
            "parents": [],
            "secId": "s0045",
            "sentence": "The economic evaluation of the vaccine does not account for indirect economic implications (e.g. productivity effects).",
            "startOffset": 59671,
            "title": "Discussion"
        },
        {
            "endOffset": 38814,
            "parents": [],
            "secId": "s0010",
            "sentence": "Individuals who tested HIV positive were not eligible for future boosters, and we did not add HIV testing to the cost.",
            "startOffset": 38696,
            "title": "Methods"
        },
        {
            "endOffset": 34206,
            "parents": [],
            "secId": "s0010",
            "sentence": "Model set-up and calibration.",
            "startOffset": 34177,
            "title": "Methods"
        },
        {
            "endOffset": 40311,
            "parents": [],
            "secId": "s0010",
            "sentence": "ART and PrEP Scale-Up Scenarios.",
            "startOffset": 40279,
            "title": "Methods"
        },
        {
            "endOffset": 33253,
            "parents": [],
            "secId": "s0005",
            "sentence": "We model the efficacy profile associated with the 5-dose regimen following the original HVTN 702 protocol and include possible booster doses following the primary series (beginning at 36 months from the first vaccination).",
            "startOffset": 33031,
            "title": "Introduction"
        },
        {
            "endOffset": 61068,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 60869,
                    "startOffset": 60862
                },
                "b0255": {
                    "endOffset": 60869,
                    "startOffset": 60862
                }
            },
            "secId": "s0045",
            "sentence": "We did not model risk compensation [15,51] i.e. increases in risky behavior by vaccine recipients, bearing in mind that a partially effective vaccine might necessitate additional counseling to prevent the false impression of full protection.",
            "startOffset": 60827,
            "title": "Discussion"
        },
        {
            "endOffset": 33541,
            "parents": [],
            "secId": "s0005",
            "sentence": "The present analysis evaluates and compares the impact and cost-effectiveness of implementation strategies initiating HIV vaccination based on targeted age groups, coverage goals, booster attrition, roll-out, HIV treatment scale-up, and oral pre-exposure prophylaxis (PrEP) availability.",
            "startOffset": 33254,
            "title": "Introduction"
        },
        {
            "endOffset": 41439,
            "parents": [],
            "secId": "s0010",
            "sentence": "In the most optimistic scenario (\u2018Fast Track with PrEP\u2019), we kept the same PrEP coverage as in scenario \u2018Status Quo with PrEP\u2019, increased testing and linkage to ART and decreased lost-to-follow-up which results in close to 90% ART coverage in 2047.",
            "startOffset": 41191,
            "title": "Methods"
        },
        {
            "endOffset": 31114,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 31113,
                    "startOffset": 31106
                },
                "b0070": {
                    "endOffset": 31113,
                    "startOffset": 31106
                }
            },
            "secId": "s0005",
            "sentence": "Recent results from an observational HIV study in rural KwaZulu-Natal suggest the highest risk of infection among women aged 18\u201328, and men aged 23\u201333 [13,14].",
            "startOffset": 30955,
            "title": "Introduction"
        },
        {
            "endOffset": 29948,
            "parents": [],
            "secId": "s0005",
            "sentence": "If this or an improved pox-protein HIV vaccine regimen is proven to be sufficiently efficacious and licensable, timely and efficient scale-up will require an evidence-based vaccine access plan that defines expectations and outlines commitments essential to making a licensed vaccine available to priority populations in South Africa and potentially beyond.",
            "startOffset": 29592,
            "title": "Introduction"
        },
        {
            "endOffset": 34445,
            "parents": [],
            "secId": "s0010",
            "sentence": "We modified EMOD-HIV v2.5, an age-stratified and individual-based network model of HIV of South Africa, to incorporate HIV vaccination according to pox-protein HIV vaccine regimens (such as the regimen currently being tested in HVTN 702).",
            "startOffset": 34207,
            "title": "Methods"
        },
        {
            "endOffset": 31715,
            "parents": [],
            "secId": "s0005",
            "sentence": "Second, a licensed vaccine may take up to a decade before being approved for widespread use in South Africa.",
            "startOffset": 31607,
            "title": "Introduction"
        },
        {
            "endOffset": 63612,
            "parents": [],
            "secId": "s0065",
            "sentence": "C.S., A.B., D.T.D., B.J.A., P.R., T.B.H., A.N.P., L.-G.",
            "startOffset": 63557,
            "title": "Author contributions"
        },
        {
            "endOffset": 59427,
            "parents": [],
            "secId": "s0045",
            "sentence": "We did not model the impact of possible changes in voluntary medical male circumcision scale-up on vaccination, nor did we model the recently added 18-month dose in the amended trial protocol.",
            "startOffset": 59235,
            "title": "Discussion"
        },
        {
            "endOffset": 48397,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Results"
                }
            ],
            "secId": "s0030",
            "sentence": "Exponential waning rates are estimated at 0.065 per month, and with each dose of ALVAC-HIV-C+gp120, incremental efficacy increases by 34%.",
            "startOffset": 48259,
            "title": "Time-dependent and cumulative vaccine efficacy"
        },
        {
            "endOffset": 55599,
            "parents": [],
            "secId": "s0045",
            "sentence": "The results of this study highlight the need to exploit different vaccination targeting and roll-out scenarios to maximize the population-level impact of a partially effective HIV vaccine in South Africa.",
            "startOffset": 55395,
            "title": "Discussion"
        },
        {
            "endOffset": 60826,
            "parents": [],
            "secId": "s0045",
            "sentence": "This is difficult to know a priori and was not included in the analysis, and therefore remains an area important to explore in close collaboration with implementers of HIV prevention programs.",
            "startOffset": 60634,
            "title": "Discussion"
        },
        {
            "endOffset": 32776,
            "parents": [],
            "secId": "s0005",
            "sentence": "In addition to bridging these gaps, the present work offers additional improvements such as application of an age-structured HIV network model, more realistic date of vaccine introduction, and complex booster schedules.",
            "startOffset": 32557,
            "title": "Introduction"
        },
        {
            "endOffset": 47422,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Results"
                }
            ],
            "secId": "s0025",
            "sentence": "For a general population aged 15\u201349, the average incidence rate in 2027 across all three scale-up and prevention scenarios is projected to be 0.81%.",
            "startOffset": 47274,
            "title": "Incidence given no HIV vaccine"
        },
        {
            "endOffset": 43652,
            "parents": [],
            "secId": "s0010",
            "sentence": "DALYs were discounted 0, 3 or 5% annually.",
            "startOffset": 43610,
            "title": "Methods"
        },
        {
            "endOffset": 46715,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Results"
                }
            ],
            "secId": "s0025",
            "sentence": "For the scenarios \u2018Status Quo without PrEP\u2019, \u2018Status Quo with PrEP\u2019 and \u2018Fast Track with PrEP\u2019, the average percentage of HIV-diagnosed individuals on ART would be 56, 55 and 85% respectively in 2027, compared to 54% in 2016 (Fig. S2).",
            "startOffset": 46480,
            "title": "Incidence given no HIV vaccine"
        },
        {
            "endOffset": 38620,
            "parents": [],
            "secId": "s0010",
            "sentence": "Booster eligibility depended on having received the primary immunization series or the booster previously.",
            "startOffset": 38514,
            "title": "Methods"
        },
        {
            "endOffset": 63515,
            "parents": [],
            "secId": "s0065",
            "sentence": "C.S., A.B., D.T.D., T.B.H., A.N.P. conceived the study and designed the experiments.",
            "startOffset": 63431,
            "title": "Author contributions"
        },
        {
            "endOffset": 43227,
            "parents": [],
            "refoffsets": {
                "b0165": {
                    "endOffset": 43226,
                    "startOffset": 43222
                }
            },
            "secId": "s0010",
            "sentence": "Health impact was summarized in disability-adjusted life years (DALYs), calculated as the present discounted value of years of healthy life lost to disability and years of life lost to premature death over a 20-year horizon of vaccination [33].",
            "startOffset": 42983,
            "title": "Methods"
        },
        {
            "endOffset": 34814,
            "parents": [],
            "secId": "s0010",
            "sentence": "This renders the model well suited for a nuanced analysis of the anticipated time-dependent efficacy of the pox-protein HIV vaccine regimen.",
            "startOffset": 34674,
            "title": "Methods"
        },
        {
            "endOffset": 34673,
            "parents": [],
            "secId": "s0010",
            "sentence": "Because EMOD is an individual-based model, interventions such as a time-varying course of vaccine efficacy can be applied to each individual according to his or her own timing of vaccination and adherence to the booster series.",
            "startOffset": 34446,
            "title": "Methods"
        },
        {
            "endOffset": 61363,
            "parents": [],
            "secId": "s0045",
            "sentence": "Finally, we likely underestimate the long-term benefits of vaccination.",
            "startOffset": 61292,
            "title": "Discussion"
        },
        {
            "endOffset": 27110,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 27019,
                    "startOffset": 27016
                }
            },
            "secId": "s0005",
            "sentence": "Despite continued efforts to scale up treatment, resulting in 18.2 million people receiving antiretroviral therapy [2], an estimated 2.1 million people (including 150,000 children) were newly infected in 2015.",
            "startOffset": 26901,
            "title": "Introduction"
        },
        {
            "endOffset": 58015,
            "parents": [],
            "secId": "s0045",
            "sentence": "Instead of using the WHO cost-effectiveness thresholds, the South African HIV/TB investment case study group developed its own CE threshold in determining the cost-effectiveness of new HIV interventions in South Africa.",
            "startOffset": 57796,
            "title": "Discussion"
        },
        {
            "endOffset": 47666,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Results"
                }
            ],
            "secId": "s0025",
            "sentence": "Without the vaccine, model projections predict an average of 0.84%, 0.76% and 0.48% annual HIV incidence in a general population aged 15\u201349 by 2047 for \u2018Status Quo without PrEP\u2019, \u2018Status Quo with PrEP\u2019  and \u2018Fast Track with PrEP\u2019  respectively.",
            "startOffset": 47422,
            "title": "Incidence given no HIV vaccine"
        },
        {
            "endOffset": 63556,
            "parents": [],
            "secId": "s0065",
            "sentence": "C.S. performed the modeling experiments.",
            "startOffset": 63516,
            "title": "Author contributions"
        },
        {
            "endOffset": 31295,
            "parents": [],
            "secId": "s0005",
            "sentence": "These epidemic patterns imply that prioritizing high levels of vaccination among young women and a slightly older age group of men would most efficiently reduce new HIV infections.",
            "startOffset": 31115,
            "title": "Introduction"
        },
        {
            "endOffset": 40935,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 40934,
                    "startOffset": 40928
                },
                "b0145": {
                    "endOffset": 40813,
                    "startOffset": 40809
                },
                "b0150": {
                    "endOffset": 40934,
                    "startOffset": 40928
                }
            },
            "secId": "s0010",
            "sentence": "These assumptions were consistent with the 60% ART coverage under current guidelines assumed in the HIV/TB Investment Case Report for South Africa [29] and reflect to some extent recent pessimistic results on treatment linkage and scale-up in South African settings [3,30].",
            "startOffset": 40662,
            "title": "Methods"
        },
        {
            "endOffset": 30422,
            "parents": [],
            "secId": "s0005",
            "sentence": "To inform the development of an access plan, the P5 Global Access Committee (short: GAC, comprised of representatives from the Bill & Melinda Gates Foundation, National Institutes of Health (DAIDS/NIAID), Sanofi Pasteur, GlaxoSmithKline and the South African Medical Research Council) has engaged in a variety of preparatory analyses -including commissioning the modelling work detailed in this article- to identify the populations that would benefit most from the vaccine.",
            "startOffset": 29949,
            "title": "Introduction"
        },
        {
            "endOffset": 38936,
            "parents": [],
            "secId": "s0010",
            "sentence": "We assumed that four booster doses after the primary first-year series were necessary to confer one decade of protection.",
            "startOffset": 38815,
            "title": "Methods"
        },
        {
            "endOffset": 32034,
            "parents": [],
            "secId": "s0005",
            "sentence": "Forecasting changes in incidence patterns is needed to predict the likely impact of implementation scenarios under consideration and design a relevant and effective scale-up strategy.",
            "startOffset": 31851,
            "title": "Introduction"
        },
        {
            "endOffset": 32556,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 32357,
                    "startOffset": 32348
                },
                "b0075": {
                    "endOffset": 32357,
                    "startOffset": 32348
                },
                "b0080": {
                    "endOffset": 32357,
                    "startOffset": 32348
                },
                "b0085": {
                    "endOffset": 32357,
                    "startOffset": 32348
                },
                "b0090": {
                    "endOffset": 32357,
                    "startOffset": 32348
                },
                "b0095": {
                    "endOffset": 32357,
                    "startOffset": 32348
                },
                "b0100": {
                    "endOffset": 32357,
                    "startOffset": 32348
                },
                "b0105": {
                    "endOffset": 32357,
                    "startOffset": 32348
                },
                "b0110": {
                    "endOffset": 32357,
                    "startOffset": 32348
                },
                "b0115": {
                    "endOffset": 32357,
                    "startOffset": 32348
                },
                "b0120": {
                    "endOffset": 32357,
                    "startOffset": 32348
                }
            },
            "secId": "s0005",
            "sentence": "Several modeling studies [3,15\u201324] have estimated impact and cost-effectiveness of an RV144-like vaccine, but all have assumed either a constant level of efficacy or exponentially waning immunity after a single course of vaccination.",
            "startOffset": 32323,
            "title": "Introduction"
        },
        {
            "endOffset": 60303,
            "parents": [],
            "secId": "s0045",
            "sentence": "Although the estimated maximum vaccine cost accounts for possible resource displacement (e.g. ART cost saving), further additional investment might be necessary to maintain treatment and prevention programs with concurrent vaccine roll-out, such that vaccine cost is likely underestimated.",
            "startOffset": 60014,
            "title": "Discussion"
        },
        {
            "endOffset": 44796,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 44795,
                    "startOffset": 44785
                },
                "b0205": {
                    "endOffset": 44795,
                    "startOffset": 44785
                },
                "b0210": {
                    "endOffset": 44795,
                    "startOffset": 44785
                }
            },
            "secId": "s0010",
            "sentence": "South Africa does not have an established cost-effectiveness threshold per DALY-averted to determine value for money, although some recent estimates are now available [29,41,42].",
            "startOffset": 44618,
            "title": "Methods"
        },
        {
            "endOffset": 36014,
            "parents": [],
            "secId": "s0010",
            "sentence": "For detailed information on the model set-up, calibration and baseline assumptions on HIV treatment and prevention other than vaccine we refer to the Supplementary Material.",
            "startOffset": 35841,
            "title": "Methods"
        },
        {
            "endOffset": 39076,
            "parents": [],
            "secId": "s0010",
            "sentence": "Vaccination Strategies for Evaluation.",
            "startOffset": 39038,
            "title": "Methods"
        },
        {
            "endOffset": 47273,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Results"
                }
            ],
            "secId": "s0025",
            "sentence": "The gender discrepancy in incidence is maintained, with a male-to-female incidence ratio between 0.57 and 0.54 in 2027 regardless of the scale-up assumptions.",
            "startOffset": 47115,
            "title": "Incidence given no HIV vaccine"
        },
        {
            "endOffset": 30787,
            "parents": [],
            "secId": "s0005",
            "sentence": "The highest HIV incidence rates are observed in young women aged 15\u201324.",
            "startOffset": 30716,
            "title": "Introduction"
        },
        {
            "endOffset": 57795,
            "parents": [],
            "refoffsets": {
                "b0250": {
                    "endOffset": 57794,
                    "startOffset": 57790
                }
            },
            "secId": "s0045",
            "sentence": "Measuring opportunity cost from a government perspective and deriving cost-effectiveness thresholds for health care interventions for particular countries is an area of active research and debate [50].",
            "startOffset": 57594,
            "title": "Discussion"
        },
        {
            "endOffset": 44617,
            "parents": [],
            "secId": "s0010",
            "sentence": "Since we assumed complete primary series, wasted doses could potentially originate only from missed two-yearly boosters.",
            "startOffset": 44497,
            "title": "Methods"
        },
        {
            "endOffset": 59234,
            "parents": [],
            "secId": "s0045",
            "sentence": "Additional sources of uncertainty include differences in regimens and study populations between RV144 and the ongoing trial, statistical uncertainty in the RV144 results, and translation of cohort efficacy data to an individual-based model in the absence of HIV exposure information for the cohort under study.",
            "startOffset": 58924,
            "title": "Discussion"
        },
        {
            "endOffset": 31411,
            "parents": [],
            "secId": "s0005",
            "sentence": "However, determining the optimal use of an HIV vaccine based on age patterns of incidence has several complications.",
            "startOffset": 31295,
            "title": "Introduction"
        },
        {
            "endOffset": 58689,
            "parents": [],
            "secId": "s0045",
            "sentence": "This reflects the fact that HIV treatment and prevention uptake is already saturated in South Africa, and suggests that only a limited number of interventions should be scaled up to avoid detrimental population health outcomes resulting from budget funds being displaced from other interventions.",
            "startOffset": 58393,
            "title": "Discussion"
        },
        {
            "endOffset": 44496,
            "parents": [],
            "secId": "s0010",
            "sentence": "This cost level included both the ALVAC and the protein component, as well as implementation cost (e.g. personnel cost of vaccine delivery, facility-level costs, supply-chain management).",
            "startOffset": 44309,
            "title": "Methods"
        },
        {
            "endOffset": 31850,
            "parents": [],
            "secId": "s0005",
            "sentence": "In the interim, nationally representative HIV epidemiologic patterns are likely to change from current data, which dates back to 2012.",
            "startOffset": 31716,
            "title": "Introduction"
        },
        {
            "endOffset": 46961,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Results"
                }
            ],
            "secId": "s0025",
            "sentence": "Likewise, for the same scenarios, annual HIV incidence in women aged 15\u201349 is projected to decline from 1.6% in 2016 to 1.21% for \u2018Status Quo without PrEP\u2019, 1.17% for \u2018Status Quo with PrEP\u2019, and 0.76% for \u2018Fast Track with PrEP\u2019 by the year 2027.",
            "startOffset": 46716,
            "title": "Incidence given no HIV vaccine"
        },
        {
            "endOffset": 60633,
            "parents": [],
            "secId": "s0045",
            "sentence": "Furthermore, different target populations may be more or less challenging to reach.",
            "startOffset": 60550,
            "title": "Discussion"
        },
        {
            "endOffset": 61291,
            "parents": [],
            "refoffsets": {
                "b0260": {
                    "endOffset": 61104,
                    "startOffset": 61100
                },
                "b0265": {
                    "endOffset": 61154,
                    "startOffset": 61150
                }
            },
            "secId": "s0045",
            "sentence": "Vaccine-induced seropositivity [52] is likely to add substantial additional cost [53] due to the need to use nucleic acid based HIV testing to distinguish HIV infections from the presence of vaccine-induced HIV antibodies.",
            "startOffset": 61069,
            "title": "Discussion"
        },
        {
            "endOffset": 55835,
            "parents": [],
            "secId": "s0045",
            "sentence": "Even under high attrition rates, providing additional booster doses for up to one decade after the primary series can increase public health impact, as long as gender-specific age ranges of highest incidence are covered by vaccination.",
            "startOffset": 55600,
            "title": "Discussion"
        },
        {
            "endOffset": 35705,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 35704,
                    "startOffset": 35697
                },
                "b0130": {
                    "endOffset": 35704,
                    "startOffset": 35697
                },
                "b0135": {
                    "endOffset": 35704,
                    "startOffset": 35697
                }
            },
            "secId": "s0010",
            "sentence": "The parameters, model input values, sources, projections, and sensitivities of the epidemic projection without vaccine, used as the reference group for comparison, have been described previously [25\u201327].",
            "startOffset": 35502,
            "title": "Methods"
        },
        {
            "endOffset": 28214,
            "parents": [],
            "secId": "s0005",
            "sentence": "It is testing a modified version of the only HIV vaccine to date that has shown evidence of efficacy in humans.",
            "startOffset": 28103,
            "title": "Introduction"
        },
        {
            "endOffset": 38354,
            "parents": [],
            "secId": "s0010",
            "sentence": "For the purpose of model projections beyond the primary trial endpoint, we also implemented up to four two-yearly boosters starting at month 36 with fixed attrition rates of 0, 20 or 50% per booster to cover a total of 10 years of vaccine efficacy.",
            "startOffset": 38106,
            "title": "Methods"
        },
        {
            "endOffset": 27653,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 27652,
                    "startOffset": 27649
                }
            },
            "secId": "s0005",
            "sentence": "However, a recent modeling study including 127 different countries suggests that the majority of countries under consideration (including South Africa) is unlikely to meet the 90-90-90 target [3].",
            "startOffset": 27457,
            "title": "Introduction"
        },
        {
            "endOffset": 55036,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "Among the simulated vaccination strategies, catch-up vaccination age 18\u201335 is the most efficient when compared to cohort vaccination, since ART cost savings as well as averted DALYs are high, despite very similar maximum vaccine cost.",
            "startOffset": 54802,
            "title": "Vaccination cost thresholds"
        },
        {
            "endOffset": 43762,
            "parents": [],
            "secId": "s0010",
            "sentence": "The launch price and implementation cost of an HIV vaccine in South Africa are unknown.",
            "startOffset": 43675,
            "title": "Methods"
        },
        {
            "endOffset": 40661,
            "parents": [],
            "secId": "s0010",
            "sentence": "We excluded any use of oral PrEP.",
            "startOffset": 40628,
            "title": "Methods"
        },
        {
            "endOffset": 43310,
            "parents": [],
            "secId": "s0010",
            "sentence": "Disability weights for HIV health states differed by CD4-count category (Table 1).",
            "startOffset": 43228,
            "title": "Methods"
        },
        {
            "endOffset": 28000,
            "parents": [],
            "secId": "s0005",
            "sentence": "October of 2016 marked the launch of the first trial in seven years to test the preventative efficacy of an HIV vaccine in humans.",
            "startOffset": 27870,
            "title": "Introduction"
        },
        {
            "endOffset": 59670,
            "parents": [],
            "secId": "s0045",
            "sentence": "Since available data on the distribution of earnings, non-healthcare consumption costs, and patient time costs in South Africa were insufficient to be included in this analysis, we adopted a government payer instead of a societal perspective.",
            "startOffset": 59428,
            "title": "Discussion"
        },
        {
            "endOffset": 28102,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 28035,
                    "startOffset": 28032
                },
                "b0030": {
                    "endOffset": 28101,
                    "startOffset": 28098
                }
            },
            "secId": "s0005",
            "sentence": "HVTN 702 is a phase 2b/3 trial [5], supported by the Pox-Protein Public-Private Partnership (P5) [6].",
            "startOffset": 28001,
            "title": "Introduction"
        },
        {
            "endOffset": 29592,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 29368,
                    "startOffset": 29364
                }
            },
            "secId": "s0005",
            "sentence": "Preliminary results of HVTN 100 [10], a small-scale clinical trial evaluating the ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59 (short: ALVAC-HIV-C+gp120) vaccine, suggest good safety, tolerability, and immunogenicity of the modified product and regimen.",
            "startOffset": 29332,
            "title": "Introduction"
        },
        {
            "endOffset": 28483,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 28482,
                    "startOffset": 28479
                }
            },
            "secId": "s0005",
            "sentence": "In 2009, RV144 showed partial reduction in HIV acquisition among community-based, predominantly heterosexual participants in Thailand using a modified intent-to-treat analysis (vaccine efficacy of 31.2% (95% CI: 1.1\u201352.1%) at month 42 after the first vaccination) [7].",
            "startOffset": 28215,
            "title": "Introduction"
        },
        {
            "endOffset": 32323,
            "parents": [],
            "secId": "s0005",
            "sentence": "Effective vaccination will prevent HIV infections not only in the direct recipients, but also in their sexual partners within the contact network.",
            "startOffset": 32177,
            "title": "Introduction"
        },
        {
            "endOffset": 44938,
            "parents": [],
            "refoffsets": {
                "b0205": {
                    "endOffset": 44937,
                    "startOffset": 44933
                }
            },
            "secId": "s0010",
            "sentence": "The cost-effectiveness threshold should represent the opportunity costs of committing scarce health system resources to an intervention [41].",
            "startOffset": 44797,
            "title": "Methods"
        },
        {
            "endOffset": 29331,
            "parents": [],
            "secId": "s0005",
            "sentence": "In addition to the six-month series tested in RV144, its original protocol comprises a booster dose at month 12, as well as a change in adjuvant (from alum to MF59) to the gp120 protein component of the vaccine, and a recently amended 18-month booster dose.",
            "startOffset": 29074,
            "title": "Introduction"
        },
        {
            "endOffset": 57203,
            "parents": [],
            "secId": "s0045",
            "sentence": "Long-term economic evaluation of vaccination suffers, in part, from the uncertainty of whether HIV treatment and prevention scale-up could be achieved between now and 2027.",
            "startOffset": 57031,
            "title": "Discussion"
        },
        {
            "endOffset": 48843,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0215": {
                    "endOffset": 48842,
                    "startOffset": 48838
                }
            },
            "secId": "s0030",
            "sentence": "For the latter case, estimated efficacy of 40% at month 39 coincides with predictions from recently developed statistical approaches using immune correlates of protection [43].",
            "startOffset": 48667,
            "title": "Time-dependent and cumulative vaccine efficacy"
        },
        {
            "endOffset": 33797,
            "parents": [],
            "secId": "s0005",
            "sentence": "Results from the present modelling analysis will help to inform ongoing vaccine access planning elements, including priority populations for whom the pox-protein HIV vaccine would be expected to have the greatest and/or most efficient public health impact.",
            "startOffset": 33541,
            "title": "Introduction"
        },
        {
            "endOffset": 45254,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 45252,
                    "startOffset": 45248
                }
            },
            "secId": "s0010",
            "sentence": "To aid with interpretation, we assumed a threshold of 1x the 2015 gross domestic product (GDP) per capita in South Africa as a cost-effectiveness threshold as well as a threshold of approximately 750 US$ per DALY averted, as determined by the South African HIV/TB investment case study group (see Table 54 in [29]).",
            "startOffset": 44939,
            "title": "Methods"
        },
        {
            "endOffset": 35502,
            "parents": [],
            "secId": "s0010",
            "sentence": "This stakeholder engagement process helped us understand perspectives on the future HIV prevention landscape, benefits of and challenges to reaching specific target populations and the economic factors that will influence vaccine access, all of which were incorporated into our analysis and considerations.",
            "startOffset": 35196,
            "title": "Methods"
        },
        {
            "endOffset": 60013,
            "parents": [],
            "secId": "s0045",
            "sentence": "The threshold analysis to determine the maximum cost-effective cost per vaccine regimen included product, delivery and implementation cost, which may vary across the simulated strategies, making cost comparisons difficult.",
            "startOffset": 59791,
            "title": "Discussion"
        },
        {
            "endOffset": 60549,
            "parents": [],
            "secId": "s0045",
            "sentence": "The lack of bounds on the vaccine price and insufficient data on other cost-drivers such as staff training, information campaigns and monitoring for such a complex regimen made it challenging to carry out a well-informed cost breakdown analysis.",
            "startOffset": 60304,
            "title": "Discussion"
        },
        {
            "endOffset": 30715,
            "parents": [],
            "secId": "s0005",
            "sentence": "In South Africa, HIV incidence varies considerably by age and sex.",
            "startOffset": 30649,
            "title": "Introduction"
        },
        {
            "endOffset": 56809,
            "parents": [],
            "secId": "s0045",
            "sentence": "The time-dependent course of vaccine efficacy necessitates aligning vaccination such that the times of highest efficacy are within the ages of highest HIV incidence in 2027 \u2013 projected to be 20\u201325 years of age for women, and five to ten years older for men (Fig. S9).",
            "startOffset": 56542,
            "title": "Discussion"
        },
        {
            "endOffset": 48666,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Results"
                }
            ],
            "secId": "s0030",
            "sentence": "Two-yearly boosters starting at month 36 will sustain durability with a maximum of 29.6% cumulative efficacy over one decade of vaccination, whereas discontinuing boosters after the first-year series yields a reduced cumulative efficacy of 14.8% (Fig. 2, green curve).",
            "startOffset": 48398,
            "title": "Time-dependent and cumulative vaccine efficacy"
        },
        {
            "endOffset": 34177,
            "parents": [],
            "secId": "s0010",
            "sentence": "As compared to a reference case with no HIV vaccine, we evaluate implementation of strategies for initiation of HIV vaccination.",
            "startOffset": 34049,
            "title": "Methods"
        },
        {
            "endOffset": 44082,
            "parents": [],
            "refoffsets": {
                "b0190": {
                    "endOffset": 43826,
                    "startOffset": 43819
                },
                "b0195": {
                    "endOffset": 43826,
                    "startOffset": 43819
                },
                "b0200": {
                    "endOffset": 43826,
                    "startOffset": 43819
                }
            },
            "secId": "s0010",
            "sentence": "Following a value-based pricing framework for medicines [38\u201340], a threshold analysis varied the vaccine cost parameter value to identify potential maximum cost-effective HIV vaccine costs (including both wholesale acquisition and implementation cost), as an average across persons receiving different numbers of doses.",
            "startOffset": 43763,
            "title": "Methods"
        },
        {
            "endOffset": 43479,
            "parents": [],
            "secId": "s0010",
            "sentence": "DALYs averted were calculated by subtracting cumulative DALYs with vaccine from those without vaccine for each of the three treatment and prevention scale-up scenarios.",
            "startOffset": 43311,
            "title": "Methods"
        },
        {
            "endOffset": 30954,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 30953,
                    "startOffset": 30946
                },
                "b0060": {
                    "endOffset": 30953,
                    "startOffset": 30946
                }
            },
            "secId": "s0005",
            "sentence": "In 2012, the estimated incidence in this age group was 2.54% per year (95% 2.04\u20133.04%), which is five times the rate of HIV incidence in young men aged 15\u201324 [11,12].",
            "startOffset": 30788,
            "title": "Introduction"
        },
        {
            "endOffset": 43674,
            "parents": [],
            "secId": "s0010",
            "sentence": "Maximum Vaccine Costs.",
            "startOffset": 43652,
            "title": "Methods"
        },
        {
            "endOffset": 39038,
            "parents": [],
            "secId": "s0010",
            "sentence": "For catch-up vaccination scenarios, booster eligibility was limited by the age range of the vaccinee.",
            "startOffset": 38937,
            "title": "Methods"
        },
        {
            "endOffset": 57593,
            "parents": [],
            "refoffsets": {
                "b0245": {
                    "endOffset": 57592,
                    "startOffset": 57588
                }
            },
            "secId": "s0045",
            "sentence": "Our analysis suggested an estimated maximum cost of 105 US$\u2013787 US$ at which vaccination with a full 10-year regimen would be cost-effective based on a 1xGDP per capita threshold [49].",
            "startOffset": 57409,
            "title": "Discussion"
        },
        {
            "endOffset": 63754,
            "parents": [],
            "secId": "s0070",
            "sentence": "The authors declare no competing interests.",
            "startOffset": 63711,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 34048,
            "parents": [],
            "secId": "s0010",
            "sentence": "We developed an agent-based model of the South African population to forecast HIV infections, disability-adjusted life-years (DALYs), and healthcare costs from a government payer perspective over a 30-year time horizon, from year 2018 to 2047.",
            "startOffset": 33805,
            "title": "Methods"
        },
        {
            "endOffset": 30649,
            "parents": [],
            "secId": "s0005",
            "sentence": "Here, target populations for vaccination were solely defined based on age and sex, although other key populations (e.g. commercial sex workers) could have similar benefits from vaccination should the product prove efficacious.",
            "startOffset": 30423,
            "title": "Introduction"
        },
        {
            "endOffset": 57031,
            "parents": [],
            "secId": "s0045",
            "sentence": "Specifically, our results indicate that, of the gender/age combinations we compared, the greatest public health impact of the pox-protein HIV vaccine would be achieved by vaccinating 18-year-old women and 23-year-old men.",
            "startOffset": 56810,
            "title": "Discussion"
        },
        {
            "endOffset": 40496,
            "parents": [],
            "secId": "s0010",
            "sentence": "To account for uncertainty in predicting the next decade of the HIV epidemic, we varied the scale-up of treatment in terms of ART and oral PrEP coverage and considered three scenarios.",
            "startOffset": 40312,
            "title": "Methods"
        },
        {
            "endOffset": 58923,
            "parents": [],
            "secId": "s0045",
            "sentence": "The time-dependent vaccine efficacy curves are based on limited data from RV144 and goals for the pox-protein vaccine regimen, and we did not consider any primary series attrition.",
            "startOffset": 58743,
            "title": "Discussion"
        },
        {
            "endOffset": 38105,
            "parents": [],
            "secId": "s0010",
            "sentence": "Booster Schedule and Efficacy.",
            "startOffset": 38075,
            "title": "Methods"
        },
        {
            "endOffset": 55384,
            "parents": [
                {
                    "id": "s0020",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "Sensitivity analyses shows that maximum vaccine cost is proportional to the CET, e.g. at a threshold of approximately 750$ per DALY averted (see Discussion for details), maximum vaccine cost would range between 22 US$ and 60 US$ under \u2018Fast Track with PrEP\u2019  assumptions and 74 US$ and 115 US$ in the \u2018Status Quo without PrEP\u2019  scenario (Fig. S8).",
            "startOffset": 55037,
            "title": "Vaccination cost thresholds"
        },
        {
            "endOffset": 32176,
            "parents": [],
            "secId": "s0005",
            "sentence": "Finally, the patterns of HIV transmission must be accounted for in order to fully capture the potential population-level impact of a vaccine.",
            "startOffset": 32035,
            "title": "Introduction"
        },
        {
            "endOffset": 42884,
            "parents": [],
            "secId": "s0010",
            "sentence": "We also estimated the number needed to vaccinate (NNV) per infection prevented, defined as the ratio of the average number of vaccine regimens distributed to the average number of new infections prevented.",
            "startOffset": 42679,
            "title": "Methods"
        },
        {
            "endOffset": 38513,
            "parents": [],
            "secId": "s0010",
            "sentence": "We assumed booster efficacy to follow the same parameterization as ALVAC-HIV-C  + gp120 doses from the primary immunization series during the first 12 months.",
            "startOffset": 38355,
            "title": "Methods"
        },
        {
            "endOffset": 38695,
            "parents": [],
            "secId": "s0010",
            "sentence": "Missing a booster resulted in loss of eligibility for subsequent boosters.",
            "startOffset": 38621,
            "title": "Methods"
        },
        {
            "endOffset": 40279,
            "parents": [],
            "secId": "s0010",
            "sentence": "Eligibility for vaccination was assumed to be independent of PrEP usage, and individuals having tested positive for HIV were not eligible for vaccination.",
            "startOffset": 40125,
            "title": "Methods"
        },
        {
            "endOffset": 40124,
            "parents": [],
            "secId": "s0010",
            "sentence": "For both roll-out scenarios, we assumed no coverage attrition for the primary immunization series.",
            "startOffset": 40026,
            "title": "Methods"
        },
        {
            "endOffset": 26900,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 26899,
                    "startOffset": 26896
                }
            },
            "secId": "s0005",
            "sentence": "With an estimated global prevalence of 36.7 million infected people as of 2015, HIV remains a public health priority in many countries [1].",
            "startOffset": 26761,
            "title": "Introduction"
        },
        {
            "endOffset": 58392,
            "parents": [],
            "secId": "s0045",
            "sentence": "Using an iterative optimization approach for all existing treatment and prevention options, the group concluded that a cost-effectiveness threshold of approximately 750 US$ per life-year saved would be an appropriate upper bound for the incremental cost to South Africa\u2019s HIV program compared to the baseline scenario (maintained coverage of all interventions at 2014 levels).",
            "startOffset": 58016,
            "title": "Discussion"
        }
    ],
    "docId": "S0264410X19302919",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "christian.selinger@gmail.com",
                "first": "Christian",
                "initial": "C.",
                "last": "Selinger"
            },
            {
                "email": null,
                "first": "Anna",
                "initial": "A.",
                "last": "Bershteyn"
            },
            {
                "email": null,
                "first": "Dobromir T.",
                "initial": "D.T.",
                "last": "Dimitrov"
            },
            {
                "email": null,
                "first": "Blythe J.S.",
                "initial": "B.J.S.",
                "last": "Adamson"
            },
            {
                "email": null,
                "first": "Paul",
                "initial": "P.",
                "last": "Revill"
            },
            {
                "email": null,
                "first": "Timothy B.",
                "initial": "T.B.",
                "last": "Hallett"
            },
            {
                "email": null,
                "first": "Andrew N.",
                "initial": "A.N.",
                "last": "Phillips"
            },
            {
                "email": null,
                "first": "Linda Gail",
                "initial": "L.G.",
                "last": "Bekker"
            },
            {
                "email": null,
                "first": "Helen",
                "initial": "H.",
                "last": "Rees"
            },
            {
                "email": null,
                "first": "Glenda",
                "initial": "G.",
                "last": "Gray"
            }
        ],
        "doi": "10.1016/j.vaccine.2019.02.073",
        "firstpage": "2258",
        "issn": "0264410X",
        "keywords": [
            "Agent-based modeling",
            "Cost-effectiveness",
            "HIV vaccine",
            "South Africa"
        ],
        "lastpage": "2267",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa"
    }
}